Gry Stensrud

Solveien 9, 1482 Nittedal, Norway
+47 91766760
gry.stensrud70@gmail.com
21. March 1970

CURRENT POSITION

2021-	Chief Technical Officer, Lytix Biopharma AS. Part of the Management team.

PREVIOUS EXPERIENCE

2010-2021	VP Technical Development and Operations, Photocure ASA, Oslo, Norway. Part of Photocure`s Management Team since 2011.
2009-2010	Director Operations, QP, Photocure ASA
2006-2009	Pharmaceutical Director, QP, Photocure ASA
2005-2006	Manager, Process and Formulation Technology. GE HealthCare*
2004	Sr. Quality Associate, QP, QA R&D. GE HealthCare
2003-2004	Sr. Scientist, Process and Formulation Research, R&D, GE HealthCare
2000-2003	Scientist, Pharmaceutical Process Development, R&D, GE HealthCare
2000	Post Doc, University of Turin, chemistry department.
1994-2000	PhD Scholar, School of Pharmacy, University of Oslo

*Former Nycomed Amersham

UNIVERSITY DEGREES

January 2000	Dr. Scient (PhD), Pharmaceutical Technology, School of Pharmacy, University of Oslo, Norway
June 1994	Cand. Pharm. (MScPharm). Master degree at University of Kiel, Germany

OTHER EDUCATION

2001	Master of Management-Project management (Oslo Business School)

KEY QUALIFICATIONS

Top management team experience; strategy development, risk assessments and evaluations, budgets/financials/costs, strategic partnerships (license -/marketing partners/customers), leadership.

Personnel, Project and Management skills, cross-functional teams. Experience with EHS and EGS reporting.

Research, development, tech transfer, validation and documentation of API, Medicinal products and Medical devices

Clinical trial supply, Commercial manufacture and distribution of API, Medicinal products and Medical Devices

Quality Systems, Quality Assurance and Quality Control (QMS,MDD/MDR,ISO, GMP, GDP).

Regulatory applications, interactions with Health Authorities and authority inspections

Establishment and Follow-up of outsourced activities, contractors and suppliers

Agreements/ Contracts/IP

PUBLICATIONS AND PATENTS

Stensrud, G., Rantanen, L., Ågren, T.L., Smistad, G. and Karlsen, J. Effects of γ-irradiation on the phase transition behaviour of phospholipids as solids and liposomes. Progress in drug delivery system 5 (1996) 9-12.

Stensrud, G., Smistad, G. and Karlsen, J. Effects of gamma irradiation on the stability of liposomes/phospholipids. 1. Chemical stability. Drug stability 1 (1996) 152-160.

Stensrud, G., Smistad,G., Ågren, T.L., Sande, S.A. and Karlsen, J. Effects of gamma irradiation on the physical stability of liposomal phospholipids. J. Liposome Res. 7 (1997) 503-528. Erratum; J. Liposome Res. 8 (1998) 297-298.

Stensrud, G., Passi, S., Larsen, T., Sandset, P.M., Smistad, G., Mönkkönen, J. and Karlsen, J. Toxicity of gamma irradiated liposomes. 1. In vitro interactions with blood components. Int. J. Pharm. 178 (1999) 33-46.

Stensrud, G., Mönkkönen, J. and Karlsen, J. Toxicity of gamma irradiated liposomes. 2. In vitro effects on cells in culture. Int. J. Pharm. 178 (1999) 47-53.

Stensrud, G., Redford, K., Smistad, G. and Karlsen, J. Effects of gamma irradiation on solid and lyophilised phospholipids. Radiation Physics and Chemistry 56 (1999) 611-622.

Stensrud, G., Sande, S.A., Kristensen, S. and Smistad, G. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int. J. Pharm. 198 (2000) 213-228.

Gløgård, C., Stensrud, G., Hovland, R., Fossheim, S. and Klaveness, J. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. Int. J. Pharm. 233 (2002) 131-140.

Gløgård, C. Stensrud, G. and Klaveness, J. Novel high relaxivity colloidal particles based on the spesific phase organisation of amphiphilic gadolinium chelates with cholesterol. Int. J. Pharm. 253 (2003) 39-48.

Gløgård, C. Stensrud, G., Klaveness, J. and Aime; S. Novel paramagnetic liposomes for radical mapping. Magn. Reson. Chem. 41 (2003) 585-588.

Lamy, L. Thomas,J. 3 , Leroux, A. Bisson,J-F., Myren,K.Godal,A , Stensrud,G and Bezdetnaya,L. Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer. Biomedicines 2022, 10, 548. https://doi.org/10.3390/ biomedicines10030548

Hjelstuen, O-K, Martinussen, G. and Stensrud, G. WO 2006/064175. Stabilised 99mTc compositions.

Klaveness, J., Stensrud, G., Godal, A., Braenden J.B., Klem, B. WO 2009/074811 A2. Use of 5-aminolevunic acid and derivatives in a solid form for photodynamic treatment and diagnosis.

Helland, O.S., Stensrud, G., Klem, B., Braenden JB., Godal A., Klaveness, J. WO 2010/142456 A1. Solid compositions comprising 5-aminolevulinic acid.

Stensrud, G. WO 2010/142457 A1. Semi-solid compositions and pharmaceutical products.

3 patent applications submitted 2022-2023 (PCT) (undisclosed).